American Century Companies
ALDX icon

American Century Companies’s Aldeyra Therapeutics ALDX Stock Holding History

American Century Companies’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,460
Closed -$168K – 2832
2025
Q4 		$168K Buy
32,460
+177
+0.5% +$909 ﹤0.01% 2729
2025
Q3 		$169K Buy
+32,283
New +$168K ﹤0.01% 2713
2025
Q1 		– Sell
-39,198
Closed -$196K – 2884
2024
Q4 		$196K Sell
39,198
-47,511
-55% -$244K ﹤0.01% 2784
2024
Q3 		$467K Buy
86,709
+33,321
+62% +$159K ﹤0.01% 2501
2024
Q2 		$177K Buy
53,388
+36,528
+217% +$143K ﹤0.01% 2746
2024
Q1 		$55.1K Buy
16,860
+4,107
+32% +$13.5K ﹤0.01% 2893
2023
Q4 		$44.8K Buy
12,753
+1,575
+14% +$4.86K ﹤0.01% 2852
2023
Q3 		$74.7K Sell
11,178
-9,329
-45% -$69.2K ﹤0.01% 2762
2023
Q2 		$172K Buy
20,507
+2,762
+16% +$27.2K ﹤0.01% 2565
2023
Q1 		$169K Buy
17,745
+4,576
+35% +$32.3K ﹤0.01% 2461
2022
Q4 		$91.7K Buy
+13,169
New +$75.3K ﹤0.01% 2467

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

American Century Companies's ALDX Position: Q1 2026 in Review

American Century Companies sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 32,460 shares — an estimated $168K sold.

American Century Companies first reported a position in ALDX in Q4 2022 and held it in 11 quarters. The position peaked at $467K in Q3 2024. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • American Century Companies reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • American Century Companies sold 32,460 Aldeyra Therapeutics shares in Q1 2026, an estimated $168K.
  • American Century Companies first reported a position in Aldeyra Therapeutics in Q4 2022 and held it in 11 quarters.
  • American Century Companies's Aldeyra Therapeutics position peaked at $467K in Q3 2024.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.